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Background: In many countries, annual immunization with inactivated influenza vaccine (IIV) is recom-
mended for children with medical risk conditions. Prior cost-effectiveness analyses found such immu-
nization to be cost saving, but assumed effectiveness against non-severe influenza outcomes and a
higher effectiveness against severe influenza outcomes than recent studies would suggest. However,
recent vaccine studies do not indicate any reduction in community or outpatient disease episodes in
IIV immunized individuals. We therefore evaluated cost-effectiveness of IIV immunization in children
with medical risk conditions in the Netherlands, assuming that IIV reduces influenza-related hospitaliza-
tion and death, but has no meaningful impact on non-severe health outcomes.
Methods: A health economic decision tree model was developed to evaluate health effects and costs of
annual IIV immunization versus no immunization. Model inputs were based on our study on
influenza-related primary care visits and other literature. Immunization was considered cost effective
if associated costs were less than €20,000 per quality-adjusted life year (QALY) gained. Probabilistic sen-
sitivity analyses were performed to assess robustness of results, and one-way sensitivity analyses and
scenario analyses were done to assess the influence of individual parameters.
Results: Annual IIV prevents an average of 1.59 influenza-related hospitalizations and 0.02 deaths per
1,000 children with medical risk conditions. This results in an expected QALY gain of 0.43 at incremental
costs of €21,564 per 1,000 children, corresponding to an incremental cost-effectiveness ratio (ICER) of
€50,297/QALY compared to no immunization. Under base case assumptions, immunization had a 5%
probability of being cost effective. Results were most influenced by vaccine efficacy against fatal influen-
za, QALY loss due to death, and mortality rate.
Conclusions: If IIV only reduces severe disease outcomes, as current evidence suggests, annual immuniza-
tion of medical risk children is unlikely to be cost effective. Results should however be interpreted with
caution as cost-effectiveness is largely dependent on incidence and QALY losses for fatal influenza, for
which evidence is scarce.
 2020 The Authors. Published by Elsevier Ltd. This is an open access articleunder the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction tion to vaccinate children with medical risk conditions annuallyInfluenza is a major cause of respiratory disease and complica-
tions, in particular in individuals with underlying medical condi-
tions, such as chronic respiratory disease, diabetes mellitus and
cardiovascular conditions. To control the influenza disease burden,
annual immunization with inactivated influenza vaccine (IIV) of
medical risk groups from six months of age is recommended in
many countries, including the Netherlands [1]. The recommenda-with IIV relies on a thin evidence base [2]. Prior cost-
effectiveness analyses found such immunization to be cost saving
[3–5], but assumed vaccine effectiveness to be around 70%, while
recent studies have shown a vaccine effectiveness of 51% against
influenza-related death [6] and of 57% against influenza-related
hospitalization [7]. More importantly, earlier cost-effectiveness
analyses assumed vaccine effectiveness against non-severe disease
outcomes. However, there is a lack of convincing evidence that IIV
immunization reduces non-severe health outcomes, including
community or outpatient episodes of acute respiratory illness. This
fuels debate on whether the current policy actually qualifies as an
efficient allocation of healthcare budgets.hildren
2 S.K. Naber et al. / Vaccine xxx (xxxx) xxxAlthough IIV immunization reduces influenza incidence in case
of adequate antigenic match between the vaccine and circulating
influenza strains [2,8], the estimated impact on respiratory disease
incidence and severity varies widely between studies and across
seasons [2,8–11]. Several studies found no, or a very limited,
impact of IIV immunization on seasonal respiratory illness occur-
rence [8,9,11–15]. Of these, two studies were performed in medical
risk children in the Netherlands, and found no impact of IIV immu-
nization on the occurrence of upper respiratory tract infections and
asthma exacerbations [11] or primary care attended respiratory ill-
ness episodes during influenza epidemic periods [12]. It is hypoth-
esized that this lack of impact results from viral interference,
where prevention of one respiratory virus infection (i.e. influenza)
influences the risk of infection by another respiratory virus [16,17].
By contrast, effectiveness against severe influenza outcomes, such
as hospitalization or death, has been widely demonstrated [6,18–
21], possibly because immunization also reduces influenza disease
severity. Prior cost-effectiveness analyses evaluating IIV immu-
nization in children considered a reduction in disease from preven-
tion of non-severe influenza episodes. It is unknown whether
immunization would still be cost effective if no reduction in non-
severe disease outcomes is assumed. Therefore, we performed a
health economic evaluation to assess the cost-effectiveness of IIV
immunization of children with medical risk conditions, assuming
immunization is effective against severe influenza outcomes,
defined as those requiring hospitalization or resulting in death,
but has no impact on non-severe outcomes occurring in the com-
munity or primary care.2. Methods
The health and economic impact of immunization in children
with medical risk conditions was evaluated as compared to no
immunization using a decision tree-type model developed in Excel
(Version 2010, Microsoft). This static type of model was chosen
because the decision to vaccinate is a yearly choice without
long-term illness consequences. Medical risk conditions included
respiratory (e.g. recurrent wheeze/asthma) and (congenital)
cardiovascular disease, diabetes mellitus, chronic kidney disease
or immunocompromising conditions (e.g. primary immunodefi-
ciency, auto-immune disease, HIV or use of immunosuppressive
medication), according to Dutch primary care guidelines [22]. Chil-
dren with medical risk conditions who develop influenza may be
admitted to the hospital, which may either result in influenza-
related death or full recovery from disease (Fig. 1). The remainderFig. 1. Decision tree of influenza vaccination
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with medical risk conditions in the Netherlands, Vaccine, https://doi.org/10.10of the Methods section first provides a detailed description of the
input parameters used in the health economic evaluation, and then
discusses model outcomes and analyses.2.1. Influenza-related hospitalization parameters
Data on the contribution of influenza to hospitalizations in
medical risk children are scarce. Jansen et al. used two indirect
methods to estimate influenza-related hospitalizations in all chil-
dren (both with and without medical risk conditions) aged 0–
1 year, 2–4 years, and 5–17 years. Age-stratified hospitalization
rates for all-cause respiratory tract infections and pulmonary dis-
ease during influenza epidemic periods were either compared to
(i) summer baseline or (ii) peri-seasonal baseline periods [23],
while adjusting for co-circulation of respiratory syncytial virus
(RSV) based on virus surveillance data. Given a lack of consensus
on the most accurate comparator, we used the average estimate
of the two baseline periods for each age group. Next, we calculated
age-specific relative risks (RRs) of influenza-related hospitalization
for children with versus without medical risk conditions using
stratified hospitalization rates from a US-based study [24]. The
overall influenza-related hospitalization rates from Jansen et al.
were then subdivided into rates for children with and without
medical risk conditions using those RRs [24] and the age-specific
prevalence of medical risk conditions from De Hoog et al. [12]
(see Appendix Table 1 for details). Using this methodology, we
derived base case hospitalization rates of 578 per 100,000 for 0–
1 year-olds, 348 per 100,000 for 2–4 year-olds, and 111 per
100,000 for 5–17 year-olds (Table 1).2.2. Influenza-related mortality parameters
As for hospitalizations, influenza-related mortality estimates for
children with medical risk conditions were not available from liter-
ature and we used mortality estimates including all children from
Jansen et al. [23] instead. For children aged 2–17 years, we aver-
aged the influenza-related mortality rate estimated from summer
and peri-seasonal baseline. For 0–1 year-olds, Jansen et al. esti-
mated zero influenza-related mortality and argued that this may
be due to a lack of power, given that other studies did observe
influenza-related deaths in infants, with generally highest mortality
in children < 1 year of age [25,26]. We therefore used the mortality
rates in Shang et al. [27] to calculate the RR of dying at 0–1 years
of age versus at 2–17 years of age. We then multiplied this RR
with the average influenza-related mortality at ages 2–17 yearsin children with medical risk conditions.
og et al., Cost-effectiveness of inactivated influenza vaccination in children
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S.K. Naber et al. / Vaccine xxx (xxxx) xxx 3from Jansen et al. to determine the mortality rate for 0–1 year-olds
in the general population. Mortality rates were then converted to
rates for children with medical risk conditions using the age-
specific percentage of influenza-related pediatric deaths found in
children with medical risk conditions from Flannery et al. [6],
and the age-specific prevalence of medical risk conditions from
De Hoog et al. [12] (see Appendix Table 2 for details). Using this
methodology, we derived base case mortality rates of 9.1 per
100,000 for 0–1 year-olds, 2.3 per 100,000 for 2–4 year-olds, 2.6
per 100,000 for 5–12 year-olds, and 3.5 per 100,000 for 13–
17 year-olds (Table 1).
As influenza-related mortality in children is rare and difficult to
measure, the uncertainty around published estimates is large. In
scenario analysis, we used mortality estimates from Wijngaard
et al. [28], who used the incidence of influenza-like illness ratherTable 1
Input parameters of decision tree model of influenza vaccination.
Parameter Base-case
value
INFLUENZA SEVERITY
Influenza-related hospitalizations per 100,000 children with medical risk
conditions
Ages 0–1 years 578.0
Ages 2–4 years 348.3
Ages 5–17 years 110.8
Influenza-related mortality per 100,000 children with medical risk conditions
Ages 0–1 years 9.1
Ages 2–4 years 2.3
Ages 5–12 years 2.6
Ages 13–17 years 3.5
VACCINE EFFICACY
Influenza-related hospitalization 57%
Influenza-related death 51%
QALY LOSS
Vaccination 0.0001
Influenza-related hospitalization 0.016
Influenza-related death (discounted) – overall (2/3 limited; 1/3
normal)
21.20
Influenza-related death (discounted) – limited life
expectancy
13.69
Influenza-related death (discounted) – normal life
expectancy
36.22
COSTS OF VACCINATION
Vaccine 10.71
GP reimbursement 11.36
Productivity loss parents 3.64
Productivity loss per parent (in hours) 2
% of parents with productivity loss 5%
Productivity loss per hour (2017 €) 36.41
Total cost per vaccine 25.71
Total cost per vaccinated child** 29.21
COSTS OF HOSPITALIZATION
GP 9.93
% of children who visit their GP prior to hospitalization 29.5%
GP cost per hour (2017 €) 33.66
Stay at ICU 1,781.31
% of hospitalized children admitted to ICU 19.3%
Median length of stay at ICU (in days) 4.5
ICU cost per day (2017 €) 2,055.25
Stay at pediatric ward 1,918.58
Median length of stay at pediatric ward (in days) 3
Ward cost per day (2017 €) 639.53
Transportation by ambulance 85.45
Cost per emergency transport (2017 €) 625.25
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with medical risk conditions in the Netherlands, Vaccine, https://doi.org/10.10than the conventional influenza positivity rate as a measure of
influenza activity, without correction for co-circulating other respi-
ratory viruses. This provides an upper bound on influenza-related
mortality. For base case and scenario analyses we also performed
probabilistic sensitivity analyses (PSA) assuming a wide range of
influenza-related mortality rates, including zero.2.3. Utility parameters
A small loss in quality of life (0.0001 QALYs, equivalent to ~ 1 h)
was assumed for getting vaccinated, of which the associated pain is
a source of anxiety and distress for many children [29]. For
influenza-related hospitalization, an average QALY loss of 0.016
(equivalent to 5.84 days) was assumed (Table 1) [30].Distribution in PSA Source(s)
*
*
*
*
*
*
*
100-Gamma(43/2,2)y Restivo et al. [18]
100-Gamma(49/3,3)y Flannery et al. [6]
Normal
(0.0001,0.00005)
Assumption
Normal
(0.016,0.00082)
Baguelin et al. [30]
Gamma
(
p
21.20,
p
21.20)
Flannery et al. [6]§
Bruijning-Verhagen et al. [31]
Statistics Netherlands [32]
|| National Health Care Institute [34]
|| National Influenza Prevention Program [54]
–
Prosser et al. [55]
Portegijs and Van den Brakel [36]
Hakkaart-van Roijen et al. [35], Statistics Netherlands
[41]
De Hoog et al. [12]
yy
Uijen et al. [37]
Hakkaart-van Roijen et al. [35], Statistics Netherlands
[40]
Beta(19.3,100–19.3) Ampofo et al. [38], De Hoog et al. [12]
Gamma(
p
4.5,
p
4.5) Ampofo et al. [38]
Hakkaart-van Roijen et al. [35], Statistics Netherlands
[40]
Gamma(
p
3,
p
3) Ampofo et al. [38]
Hakkaart-van Roijen et al. [35], Statistics Netherlands
[40]
Hakkaart-van Roijen et al. [35], Statistics Netherlands
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Table 1 (continued)
Parameter Base-case
value
Distribution in PSA Source(s)
% of hospitalized children admitted to ICU 19.3% Beta(19.3,100–19.3) Ampofo et al. [38], De Hoog et al. [12]
Ambulance use in hospitalized children admitted to ICU 50% Assumption
Ambulance use in hospitalized children not admitted to
ICU
5% Assumption
Productivity loss parents 994.02
Length of hospitalization (in days) 3 Gamma(
p
3,
p
3) Ampofo et al. [38]
Productivity loss per hospitalization day (in hours)§§ 9.1 Friesema et al. [39]
Productivity loss per hour (2017 €) 36.41 Hakkaart-van Roijen et al. [35], Statistics Netherlands
[41]
Total cost per hospitalization 4,789.29
GP = general practitioner; ICU = intensive care unit; PSA = probabilistic sensitivity analyses.
* We simulated hospitalization and death rates for children in the general population instead of for children with medical risk conditions, because for the latter, associated
distributions could not be retrieved from literature. See Appendix Table 1 for the derivation of influenza-related hospitalization rates based on the assumed distributions
within the general population, the calculation used to determine the rates for children with medical risk conditions, and sources used. Appendix Table 2 provides a similar
overview for influenza-related mortality rates.
y Neither a Gamma distribution with alpha = mean and beta = 1, nor a Gamma distribution with alpha = beta=
p
mean gave a proper fit, so parameters were slightly adjusted.
Vaccine efficacy against influenza-related hospitalization was assumed to be 70% correlated with vaccine efficacy against influenza-related death. One shared random
number was drawn for both parameters, which accounted for 70% of the final random number, and one unique random number was drawn for both parameters, which
accounted for 30% of the final random number.
 A value of 0 was assumed if simulated values were negative.
§ Based on the medical risk conditions observed in deceased children, we suspect that two thirds of deceased children with medical risk conditions would have had a
(severely) limited life expectancy otherwise.
|| The vaccine price and the GP visit that is considered in the vaccination price are fixed reimbursement values, and were therefore not varied.
– The productivity loss of parents due to vaccination was not varied because it is both a small fraction of the total cost per vaccinated child and it is based on three inputs that
are characterized by limited uncertainty. We assumed 2 h of productivity loss per parent, which is in line with findings from Prosser et al. [55] and seems reasonable given the
time needed to visit a GP in the Netherlands. The assumption that 5% of parents need to take time off from work is based on the fact that vaccination hours are often flexible,
and that in only 10% of households with minors, both parents work full time [36] and thus potentially have to take time off. The average hourly wage was taken from the Cost
manual of the Netherlands Health Care Institute [35], which prescribes reference prices for health economic evaluations, and was updated to 2017€ using the development of
wages in collaborative labor agreements.
** Vaccination protocol prescribes that children below the age of 6 years, who are vaccinated for the first time, should receive two influenza shots, one month apart.
Approximately 14% of all children with a medical risk condition did not have a medical risk condition one year earlier and is below the age of six years. Costs per vaccinated
child were therefore 1.14 times the cost per vaccine shot.
yy The GP costs per hospitalization were not varied because it is both a small fraction of the total cost per hospitalization and it is based on two inputs that are characterized
by limited uncertainty. The percentage of children who visit their GP prior to hospitalization was taken from a Dutch study, where 23 out of 78 hospitalized children with
diagnosed pneumonia or influenza had consulted their GP (Uijen et al. [37]. The GP price per hour was taken from the Cost manual of the Netherlands Health Care Institute
[35], which prescribes reference prices for health economic evaluations, and was updated to 2017€ using the consumer price index for health care expenditures.
 The probability of ICU admittance during hospitalization was calculated based on findings from a US-based study (Ampofo et al. [38] and a Dutch study (De Hoog et al. [12].
The former study showed that 13% of the 6–23 month-old and 20.3% of the >2 year-old children who were hospitalized due to influenza, were admitted to the ICU during
hospitalization. Based on results from the latter study, we estimated that from all medical risk children that were hospitalized due to influenza-related disease, 14.2% was
<2 years old and 85.8% was 2 years old.
§§ No data available on parental productivity loss due to influenza-related hospitalizations in children in the Netherlands, so data on gastroenteritis hospitalizations was used
instead.
4 S.K. Naber et al. / Vaccine xxx (xxxx) xxxBased on the distribution of underlying medical risk conditions
among fatal influenza cases as described in Flannery et al. [6], we
assumed that two thirds of the deceased children with medical risk
conditions would otherwise have had a limited life expectancy (i.e.
comparable to Bruijning-Verhagen et al. [31]), and one third would
otherwise have had a normal life expectancy [32]. We further
assumed that given their chronic medical conditions, the quality
of life for children who die from influenza would have been 10%
lower than the average age-specific quality of life in the Nether-
lands for the remainder of their lives [33].
2.4. Cost parameters
The analysis was performed from a modified societal perspec-
tive, including both direct health care costs and productivity losses
for work absenteeism among parents.
The average costs per influenza dose equaled €25.71, consisting
of costs of the vaccine (€10.71) [34], general practitioner (GP)
(€11.36), and average productivity loss for parents (€3.64). For
the latter, we assumed that a parent would be absent from paid
work (for a period of 2 h of €36.41 each, according to Dutch cost
guidelines [35]) in only 5% of cases, because a vast majority of chil-
dren lives with at least one parent that does not work full time [36]
and both immunization hours and working hours may be flexible.
Each year, approximately 14% of all children with medical risk con-Please cite this article as: S. K. Naber, P. C. J. L. Bruijning-Verhagen, M. L. A. de Ho
with medical risk conditions in the Netherlands, Vaccine, https://doi.org/10.10ditions are aged < 6 years and are invited for influenza immuniza-
tion for the first time [12]. These children are recommended to
receive two doses, one month apart, and hence total costs per vac-
cination were increased by 14% to €29.20.
The average costs per influenza-related hospitalization were
derived from item costs, multiplied by their resource consumption.
On average 29% of children were assumed to visit their GP prior to
hospitalization [37], at costs of €33.66 per visit [35]. Median length
of stay at the pediatric ward was assumed to be 3.0 days [38], at
costs per day of €639.53 [35]. An estimated 19.3% of hospitalized
children were assumed to require intensive care unit (ICU) admis-
sion for a median duration of 4.5 days [38], at costs of €2,055.25
per day [35]. We assumed that 50% of children admitted to ICU,
and 5% of hospitalized children not requiring ICU, were transported
by ambulance (€625.25 per ride [35]). Average parental productiv-
ity loss was estimated using the average length of hospitalization
(3.0 days) and assuming 9.1 h of work leave per hospitalization
day [39], at a cost of €36.41 per hour [35]. Thus, total hospitaliza-
tion costs were estimated at €4,789.30 (GP: €9.94, pediatric ward
days: €1,918.58, ICU stay: €1,781.31, ambulance use: €85.45, par-
ental productivity losses: €994.02).
All healthcare costs were updated to 2017 euros, using the con-
sumer price index for education, healthcare and social security for
all healthcare-related costs [40]. Costs for productivity losses were
updated based on the development of salaries within collectiveog et al., Cost-effectiveness of inactivated influenza vaccination in children
16/j.vaccine.2020.01.057
S.K. Naber et al. / Vaccine xxx (xxxx) xxx 5labor arrangements wages [41]. An overview of all base case costs,
their sources, and distribution in PSA, is provided in Table 1.
2.5. Vaccine efficacy parameters
A recent systematic review and meta-analysis estimated the
average vaccine effectiveness against influenza-related hospital-
ization in children at 57% (95% confidence interval (CI): 30–74%)
[18]. A recent Australian study found that the efficacy of influenza
immunization against severe disease (i.e. visit to an emergency
department) was similar in children with and without medical risk
conditions [42]. Hence, we assumed an average vaccine effective-
ness of 57% against hospitalization for our population of medical
risk children (Table 1).
Flannery et al. found that influenza immunization (inactivated
or live-attenuated) in children with a medical risk condition
reduces risk of influenza-related death by 51% (credibility interval:
31–67%) [6]. No separate estimate was provided per vaccine type,
but the majority (81%) of children was vaccinated with the inacti-
vated influenza vaccine, which is also used in the Netherlands. To
our knowledge, this is the only study providing estimates on vac-
cine effectiveness against mortality.
The model did not allow for any herd effect, i.e. a reduction of
influenza incidence in non-immunized children as a result of
immunizing others. We believe that such an effect would be small,
given that healthy children and adults below age 60 are not rou-
tinely vaccinated in the Netherlands.
2.6. Model outcomes
Model outcomes include the number of vaccines, hospitaliza-
tions, and deaths, as well as the associated costs and health effects
per 1,000 vaccinated, and per 1,000 unvaccinated children with
medical risk conditions. Vaccination impact and (cost-)
effectiveness was calculated using the difference in costs and
health effects between those groups. In the Discussion, the findings
are extrapolated to the Netherlands, using the child population size
from Statistics Netherlands [43], and the prevalence of medical risk
conditions and IIV immunization coverage from De Hoog et al. [12]
2.7. Analyses
We estimated the difference in costs and QALYs comparing a
strategy of annual IIV immunization of children with medical risk
conditions to a strategy of no immunization. The incremental cost-Table 2
Expected health effects and costs of influenza vaccination and no influenza vaccination pe
Unvaccinated cohort (N = 1,
Mean
Numbers
Vaccination 0
Hospitalization 2.747
Death 0.047
Costs (€)
Vaccination 0
Hospitalization 13,181
Total Costs 13,181
QALY losses
Vaccination 0.000
Hospitalization 0.044
Death 1.000
Total QALY loss 1.044
Overall Costs of Vaccination (€)
Overall QALYs gained by Vaccination
Average Cost per QALY gained (€)
CI = confidence interval; NA = not applicable; QALY = quality-adjusted life year.
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tal costs of immunization by the incremental QALYs, and compared
to a willingness-to-pay (WTP) threshold of €20,000 per QALY,
which is generally recommended for preventive interventions in
the Netherlands [44]. QALYs lost due to influenza-related death
were discounted at an annual rate of 1.5%. For all other outcomes,
no long term effect was assumed, and hence no discounting was
required.
We performed PSA with 10,000 simulations, in which we took
into account the uncertainty in vaccine efficacy against
influenza-related hospitalization and death, hospitalization and
mortality rates, costs of hospitalization, and QALY loss due to
immunization, hospitalization and death. The assumed distribu-
tions for these parameters and the assumptions for correlation
between vaccine efficacy against hospitalization and vaccine effi-
cacy against death, and those between hospitalization rates and
death rates, are given in Table 1. For each of the parameters varied
in the PSA, we also performed one-way sensitivity analyses in
order to assess their individual impact on the estimated outcomes.
In these analyses, parameter values were decreased and increased
by 50%, in line with best practices identified by the ISPOR-SMDM
Modeling Good Research Practices Task Force [45].
In the base-case scenario we assume hospitalization and mor-
tality rates based on Jansen et al. [23] and a reduced life expec-
tancy and quality of life for medical risk children who die from
influenza (as described in the utilities section). Given the uncer-
tainty in these assumptions, we also performed scenario analyses
in which we assumed:
(1) Mortality estimates from Wijngaard et al. [28] instead of
from Jansen et al. [23], and that
(2) Children who die from influenza were assumed to otherwise
have had a normal life expectancy and normal quality of life.
For this analysis, we used the life expectancy of the average
8-year-old child in the Netherlands [32] (i.e. the average age
at death due to influenza in children [12,23,27]), and the
average age-specific quality of life in the Netherlands [33].
Furthermore, we performed an analysis from the healthcare
perspective, excluding parental productivity losses.3. Results
Influenza immunization of medical risk children is expected to
prevent an average of 1.59 influenza-related hospitalizations (95%r 1,000 children.
000) Vaccinated cohort (N = 1,000)
95% CI Mean 95% CI
NA 1136 NA
2.360–3.155 1.154 0.899–1.422
0.006–0.096 0.023 0.003–0.047
NA 29,208 NA
9,849–17,034 5,538 3,892–7,502
9,849–17,034 34,746 33,099–36,710
NA 0.114 0.001–0.225
0.037–0.052 0.018 0.014–0.023
0.120–2.290 0.483 0.059–1.107
0.160–2.335 0.615 0.172–1.240
21,564 17,842–24,674
0.429 0.052–1.169
50,297 NA
og et al., Cost-effectiveness of inactivated influenza vaccination in children
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6 S.K. Naber et al. / Vaccine xxx (xxxx) xxxCI: 1.01–2.20) and 0.02 influenza-related deaths (95% CI: 0.00–
0.05) per 1,000 children annually, as compared to no immunization
(Table 2). This results in an expected QALY gain of 0.43 (95% CI:
0.05–1.17) and additional costs of €21,564 (95% CI: €17,842–
24,674) per 1,000 children, corresponding to an average ICER of
€50,297/QALY (Fig. 2A). Applying the Dutch recommended WTP
threshold of €20,000/QALY, there is a 5% probability that annual
immunization is cost effective compared to no immunization
(Fig. 3A).
The impact of increasing and decreasing individual input
parameters by 50%, while leaving all other parameters at their base
case value, is shown in Fig. 4. Varying the vaccine efficacy against
death had the largest impact on the ICER. Results varied from
€25,509/QALY at 77% efficacy to €187,204/QALY at 26% efficacy.
Mortality rate and QALY loss due to influenza-related death were
also highly influential on the ICER, with values ranging from
€33,208 to €136,615 per QALY in one-way sensitivity analyses. In
none of the one-way sensitivity analyses, the lower end of the ICER
range was below the €20,000/QALY threshold.
Compared to the base-case analysis, cost-effectiveness of
immunization was more favorable in the scenario analyses. When
influenza-related mortality estimates from Wijngaard et al. were
used, 0.70 more QALYs were gained per 1,000 children and, as
such, the average ICER decreased to €19,104/QALY (Fig. 2B). Cost-
effectiveness of immunization was still uncertain as the probability
of the ICER being below the €20,000/QALY threshold was 52%
(Fig. 3B). Assuming both a normal life expectancy and a normal
quality of life for children who deceased from influenza resulted
in 0.47 more QALYs gained compared to the base case, resulting
in an average ICER of €24,108/QALY (Fig. 2C). Annual immuniza-
tion then had a 35% probability of being cost effective (Fig. 3C).Fig. 2. Incremental cost-effectiveness of influenza vaccination versus no influenza vaccin
three alternative scenarios.
Please cite this article as: S. K. Naber, P. C. J. L. Bruijning-Verhagen, M. L. A. de Ho
with medical risk conditions in the Netherlands, Vaccine, https://doi.org/10.10When productivity losses for parental absenteeism from work
were excluded, costs decreased by €2,567 per 1,000 children,
resulting in an average ICER of €44,392 (Fig. 2D). In this analysis,
using a healthcare perspective, immunization had a 8% probability
of being cost effective (Fig. 3D).4. Discussion
Using a decision tree-type of model and considering vaccine
effects on influenza hospitalizations and deaths, we found that
annual IIV in children with medical risk conditions is unlikely to
be cost effective, when assuming a WTP threshold of €20,000/
QALY. The overall impact of annual immunization of medical risk
children is limited with 1.59 fewer influenza-related hospitaliza-
tions and 0.02 fewer deaths per 1,000 children, resulting in an
expected QALY gain of 0.43 per 1,000 children. These estimates
correspond to a number needed to vaccinate (NNV) of 628 to pre-
vent one hospitalization and a NNV of more than 40,000 to prevent
one death. Costs of immunization were on average €21,564 per
1,000 children, resulting in an average cost-effectiveness ratio of
€50,297/QALY. Results were highly influenced by vaccine efficacy
against death, influenza-related mortality rates, and QALY loss
due to death. However, even when assuming mortality rates based
on ILI incidence, the probability of IIV immunization being cost
effective was not higher than 52%.
On January 1st 2017, there were 3.4 million children under 18
in the Netherlands [43]. Based on the age-specific prevalence of
medical risk conditions in GP data obtained by De Hoog et al.
[12], approximately 129,000 children (3.8% of total) were eligible
for influenza immunization in 2017. In an average influenza sea-ation – Results of probabilistic sensitivity analyses under base case assumptions and
og et al., Cost-effectiveness of inactivated influenza vaccination in children
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Fig. 3. Probability that influenza vaccination is cost effective for different willingness-to-pay thresholds – Results of probabilistic sensitivity analyses under base case
assumptions and three alternative scenarios.
S.K. Naber et al. / Vaccine xxx (xxxx) xxx 7son, vaccinating all these children could potentially prevent an
estimated 200 influenza-related hospitalizations and 3 influenza-
related deaths. This would result in 53 QALYs gained at an annual
cost of €2,809,000. With ~29% vaccination coverage as observed in
De Hoog et al. [12], an estimated 59 hospitalizations and 1 death
are prevented each year, resulting in 15 QALYs gained at an annual
cost of €828,000.
Results of any cost-utility analysis are dependent on utility
assumptions. For any simulated health intervention or disease
state, average disutility and duration should be defined for the
population of interest. For (small) children, utility values are dif-
ficult to elicit [46]. However, one-way sensitivity analyses
showed that varying the assumed utility loss for vaccination
and hospitalization does not affect our conclusions. Utility loss
assumed for death did have a larger impact. If deceased children
would otherwise have had a normal quality of life, the ICER of
influenza vaccination in medical risk children was more favor-
able but it was still unlikely to be cost effective. One may argue
that severe outcomes like hospitalization and in particular the
death of a child will affect quality of life of parents as well. To
our knowledge, there is no consensus on how this parental QALY
loss should be addressed in economic evaluations of vaccination
strategies and it is generally not included. Including such paren-
tal utility losses would likely improve cost-effectiveness of IIV in
medical risk children.Please cite this article as: S. K. Naber, P. C. J. L. Bruijning-Verhagen, M. L. A. de Ho
with medical risk conditions in the Netherlands, Vaccine, https://doi.org/10.10Cost-effectiveness of influenza vaccination may be more favor-
able in one year versus another, because IIV effectiveness can vary
substantially from year-to-year depending on the antigenic match
between the vaccine and circulating influenza strains. However,
policy makers are forced to make decisions based on expected
effectiveness and cost-effectiveness, which depend on average out-
comes and their potential variation. We accounted for this by using
parameter values based on average season outcomes. For example,
we excluded the pandemic year 2009/2010 from the mortality esti-
mates obtained fromWijngaard et al. [28], which were assumed in
one of the scenario analyses. The impact of the potential variation
in vaccine effectiveness and severity of the influenza season was
explored in PSA.
Vaccine efficacy estimates used in this study are mostly based
on trivalent inactivated influenza vaccines, which are currently in
use in the Netherlands, and the reported efficacy against any
influenza, irrespective of influenza strain or subtype. The use of
quadrivalent inactivated or live-attenuated vaccines could improve
overall vaccine efficacy against hospitalization and death in chil-
dren, since they include a second influenza B strain. However, in
our one-way sensitivity analysis, increased vaccine efficacy up to
77% did not result in a mean ICER below the €20,000/QALY
threshold.
In recent years, economic evaluations of influenza immuniza-
tion in children have predominantly focused on universal immu-og et al., Cost-effectiveness of inactivated influenza vaccination in children
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Fig. 4. Tornado diagram showing the impact of reducing (50%) and increasing (+50%) input parameter values one-by-one on the incremental cost-effectiveness ratio (ICER)
of vaccination versus no vaccination.
8 S.K. Naber et al. / Vaccine xxx (xxxx) xxxnization, comparing strategies that target various age groups or
that use different influenza vaccines. Some have also evaluated
universal versus risk-group strategies, but none have recently com-
pared immunization versus no immunization within a group of
children with medical risk conditions as was done in the current
analysis. Such studies have been performed in the early days of
influenza immunization, and generally concluded that immuniza-
tion of medical risk children was cost saving [3–5]. However, the
estimated number of influenza-related hospitalizations and deaths
that would be prevented by immunization of medical risk children
was substantially higher than the more recent estimates from
developed countries suggest [47–51]. In addition, these studies
all included immunization benefits on non-severe influenza out-
comes, which were not considered in the current analysis because
of the lack of evidence already described.
Some limitations are noteworthy. First, limited evidence was
available specifically for children with medical risk conditions in
the Netherlands. While some parameters might not differ between
children with or without medical risk conditions, parameters like
hospitalization and mortality rates are likely to differ. We
accounted for this by adjusting the rates for the general population
using the increased hospitalization risk and the proportion of pedi-
atric influenza-related deaths that is found in children with medi-
cal risk conditions in US-based studies [6,24] as a proxy for the
Netherlands (Appendix Tables 1 and 2). If the risk difference
between children with and without medical risk conditions were
very different in the Netherlands compared to the US, then this
assumption may have biased the results of the PSA. However, a
50% increase in either the hospitalization or mortality risk did
not result in an ICER below €20,000 per QALY. In one-way sensitiv-
ity analyses, we evaluated which parameters were most influential
for the anticipated cost-effectiveness of IIV immunization, provid-
ing directions for further research. A formal value of information
analysis would be helpful in directing future research funds. Sec-
ond, the static model structure did not allow for interactions
between simulated individuals, which are needed to estimate the
impact of herd protection. However, without an annual IIV pro-Please cite this article as: S. K. Naber, P. C. J. L. Bruijning-Verhagen, M. L. A. de Ho
with medical risk conditions in the Netherlands, Vaccine, https://doi.org/10.10gram for children without medical risk children in the Netherlands,
and with imperfect coverage among children with medical risk
conditions, the annual IIV coverage among Dutch children is only
~1%. At such low coverage levels, estimated vaccination impact is
hardly influenced by model structure [52], and the use of a
dynamic model is unlikely to have changed our conclusions. Of
note, if universal child immunization is considered as alternative
scenario, herd protection effects should be considered, as dynamic
modeling studies suggest this has significant impact on cost-
effectiveness estimates [53]. In fact, herd protection could render
universal vaccination a more favorable scenario compared to the
risk-group based pediatric program for the Netherlands, but this
should be further evaluated.
5. Conclusions
Based on our health economic evaluation, the current policy of
IIV immunization of children with medical risk conditions is unli-
kely to be cost effective in the Netherlands. Whether IIV immu-
nization is cost effective largely depends on influenza-related
hospitalization and mortality estimates, for which evidence is
scarce. More research on these outcomes is required to come to a
final conclusion on whether annual IIV immunization in children
with medical risk conditions is cost effective, and if so, under what
specific circumstances.
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